Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Preferred Shares (2023 - 2025)

Historic Preferred Shares for SAB Biotherapeutics (SABSW) over the last 3 years, with Q3 2025 value amounting to $64.0.

  • SAB Biotherapeutics' Preferred Shares rose 118000.0% to $64.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $64.0, marking a year-over-year increase of 118000.0%. This contributed to the annual value of $5.0 for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Preferred Shares is $64.0, which was up 118000.0% from $5.0 recorded in Q2 2025.
  • SAB Biotherapeutics' Preferred Shares' 5-year high stood at $64.0 during Q3 2025, with a 5-year trough of $5.0 in Q4 2023.
  • Over the past 3 years, SAB Biotherapeutics' median Preferred Shares value was $5.0 (recorded in 2023), while the average stood at $12.38.
  • In the last 5 years, SAB Biotherapeutics' Preferred Shares changed by 0.0% in 2024 and then soared by 118000.0% in 2025.
  • Quarter analysis of 3 years shows SAB Biotherapeutics' Preferred Shares stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then surged by 1180.0% to $64.0 in 2025.
  • Its last three reported values are $64.0 in Q3 2025, $5.0 for Q2 2025, and $5.0 during Q1 2025.